PNC-27
p53-derived anticancer research peptide
A synthetic peptide studied in cancer-research literature for its membrane-disrupting activity.
Also referenced as: PNC27, p53(12-26)-MRP peptide
Overview
PNC-27 is a synthetic research peptide combining a segment of the p53 protein (residues within the HDM2-binding domain) fused to a membrane-penetrating (leader) sequence. It was developed in academic cancer research to target tumor cells.
At a glance
What PNC-27 does
PNC-27 is a chimeric research peptide built to kill cancer cells by physically breaking their membranes rather than by acting on an intracellular target. It fuses two functional pieces: a ~12-residue segment derived from the p53 protein's transactivation domain (residues 12-26, the part of p53 that normally binds HDM2/MDM2) and a membrane-resident penetratin-type 'leader' sequence that anchors the peptide into lipid bilayers. The reported selectivity hinges on an unusual observation from the originating labs: many cancer cells display HDM2 at the plasma membrane, whereas normal cells largely keep HDM2 intracellular.
Mechanistically, the model is that PNC-27's p53 domain docks onto membrane-expressed HDM2 on the cancer-cell surface, positioning the peptide so its membrane-resident portion inserts into the bilayer. Multiple PNC-27 molecules are proposed to co-assemble into transmembrane pore-like structures, causing rapid membrane permeabilization, leakage of cellular contents, and a fast, necrosis-like cell death that is independent of the classical apoptotic (caspase) cascade. Because the killing is a direct membrane event, it does not require the cell to have functional wild-type p53.
The evidence base is entirely preclinical: in-vitro work across numerous human cancer lines (leukemia, breast, pancreatic, and others) and some rodent xenograft studies, largely from a small set of groups. Reported tumor selectivity depends on the membrane-HDM2 premise, which is not universally replicated, and there are no human clinical trials. PNC-27 should be read as an experimental cytotoxic peptide of research interest, not an established therapy.
Effects reported in research
- In cultured human cancer lines (leukemia, breast, pancreatic and others), induced rapid, necrosis-like cell death by permeabilizing the plasma membrane rather than triggering apoptosis (in-vitro only).
- Reported to bind HDM2 (MDM2) presented at the cancer-cell surface via its p53(12-26)-derived domain, the docking step proposed to underlie tumor selectivity (in-vitro, mechanistic model).
- Its membrane-resident leader sequence inserts into lipid bilayers and, with multiple copies, forms transmembrane pore-like structures causing content leakage (in-vitro/biophysical studies).
- Killed cancer cells independently of functional wild-type p53, consistent with a direct membrane mechanism rather than transcriptional p53 signaling (in-vitro).
- Showed relative sparing of several normal cell types in the originating studies, attributed to low membrane HDM2 on non-cancer cells (in-vitro; selectivity not universally reproduced).
- Reduced tumor burden in some rodent xenograft models in early reports (animal only, limited groups).
- No human clinical trial data exist; all reported effects are preclinical and from a narrow body of literature.
Effects listed reflect findings reported in the research literature — many in animal or in-vitro models. Listing an effect is not a claim of efficacy or a therapeutic indication in humans.
Mechanism of action
PNC-27 contains a p53-derived domain that binds HDM2 (MDM2) coupled to a membrane-resident peptide (MRP) penetratin-type sequence. In published cell studies, PNC-27 is proposed to bind HDM2 that is expressed at the membrane of cancer cells, forming transmembrane pore-like structures that cause selective membrane disruption and necrosis of tumor cells while reportedly sparing normal cells. This mechanism is distinct from classical intracellular p53 transcriptional activity and remains preclinical.
Mechanistic description reflects published research-literature understanding. Much peptide research is preclinical (in-vitro or animal-model); mechanism in humans may differ and is not established for many compounds.
What it's studied for
Research contexts in which PNC-27 appears in the literature. Listing a research area is not a claim of efficacy or a therapeutic indication.
Key characteristics
- Chimeric peptide: p53-derived HDM2-binding domain plus a membrane-penetrating leader sequence.
- Proposed to target membrane-expressed HDM2 on cancer cells.
- Reported to cause selective tumor-cell membrane disruption/necrosis in studies.
- Mechanism differs from classical intracellular p53 signaling.
- Strictly preclinical / research-only with no approved use.
Reported research dosing reference only
Educational reference, not dosing guidance. The figures below summarize amounts reported in published research and research-community protocols, provided for educational and research context only. They are not medical advice, not a recommendation, and not instructions for human use. PNC-27 is a research compound.
PNC-27 is studied almost exclusively in vitro and in animal models, where exposure is expressed as culture concentration or per-animal amounts rather than standardized human-style dosing. No validated human research dosing protocol exists in the literature.
- In vitro studies: micromolar culture concentrations applied to cancer cell lines (concentration-dependent effects reported)
- Rodent/xenograft studies: per-animal microgram-to-milligram amounts reported in individual papers, not standardized
These are reference figures for research context only, not dosing guidance for humans. Reported values vary widely between studies and no consensus protocol exists.
How it compares
PNC-27 is a research anticancer peptide acting through a p53/HDM2 membrane-disruption mechanism, unlike the hormonal and cosmetic peptides in this set.
Handling & Stability
Lyophilized peptides are stored cold, protected from light, and reconstituted only at the time of intended in-vitro work.
- Avoid repeated freeze-thaw cycles
- Verify supplier lot and Certificate of Analysis
- Follow institutional lab-safety protocols
Analytical & COA Concepts
Reputable research suppliers publish a third-party Certificate of Analysis per batch. Key analytical concepts referenced in COAs include:
Category Context
PNC-27 sits in the Specialty & Research area of the PeptiDex library.
- Entry type: Research compound reference
- Specialty & Research category hub →
- Browse the full library →
- Glossary of terms →
Where researchers source PNC-27
For researchers studying PNC-27, third-party suppliers such as Practically Natty Peptides offer research-grade material, third-party tests every batch and provides Certificates of Analysis on request, and ship from the US. This specific listing is currently marked out of stock — check the supplier site for current availability.
View research-supplier listing →
Outbound link to a third-party research supplier. Inclusion does not constitute endorsement; all editorial content is developed independently.
Frequently asked questions
What is PNC-27 and what class of peptide is it?
PNC-27 is a synthetic chimeric peptide combining an HDM-2 (human MDM2) binding domain derived from residues 12-26 of the p53 protein with a membrane-penetrating (penetratin/leader) sequence. It is studied as an anticancer research peptide rather than as a metabolic or regenerative agent. It belongs to the class of p53-based, membrane-active peptides.
What is PNC-27 studied for?
In published research it is investigated for its reported ability to selectively induce necrosis in cancer cell lines while sparing untransformed cells in vitro. The proposed mechanism involves binding to HDM-2 present in the plasma membranes of cancer cells, leading to transmembrane pore formation and cell lysis. All work is preclinical (cell-culture and animal models); it is not an approved therapy.
How is PNC-27's mechanism thought to differ from small-molecule MDM2 inhibitors?
Small-molecule MDM2 inhibitors typically act intracellularly to disrupt the p53-MDM2 interaction and restore p53 signaling. PNC-27 research instead describes a membrane-directed mechanism: it is reported to bind HDM-2 anomalously expressed in the cancer cell membrane, forming pores rather than working through nuclear p53 restoration. This membrane-selectivity is the central research hypothesis.
How is PNC-27 typically supplied and stored for research?
PNC-27 is generally supplied as a lyophilized powder that is reconstituted for in vitro or in vivo research use. As with most peptides, lyophilized material is stored frozen and protected from light, with reconstituted solution kept refrigerated and used within a limited window. A certificate of analysis (COA) documenting purity by HPLC and identity by mass spectrometry is standard to expect.
Is PNC-27 an approved drug?
No. PNC-27 has not been approved by any regulatory agency and remains a research-only compound studied in laboratory and preclinical settings. Reported findings come from in vitro and animal work and have not been validated in controlled human clinical trials.
Answers are educational summaries of research-literature context and do not constitute medical advice. See the Research Library, COA guide, and Storage & Handling guide for more.
References
Primary literature indexed in PubMed for PNC-27. Listing a study records that it exists and is indexed — it is not a claim of efficacy, a therapeutic indication, or an endorsement of its conclusions. Much of this literature is preclinical (in-vitro or animal-model).
- Anticancer peptide PNC-27 adopts an HDM-2-binding conformation and kills cancer cells by binding to HDM-2 in their membranes
- PNC-27, a Chimeric p53-Penetratin Peptide Binds to HDM-2 in a p53 Peptide-like Structure, Induces Selective Membrane-Pore Formation and Leads to Cancer Cell Lysis
- Targeting Membrane HDM-2 by PNC-27 Induces Necrosis in Leukemia Cells But Not in Normal Hematopoietic Cells
Each reference was checked against its PubMed record on 2026-07-28: the PMID resolves and the title, journal and year match. Where no indexed literature exists for a compound, PeptiDex says so rather than substituting a citation about a different molecule. See the editorial policy.